Abstract: Injector devices and methods for using them to deliver medicament into a patient's body, e.g., sub-retinally within an eye, are provided. The injector includes an injector cannula having a soft injector tip. A retractable tip protector tube is slidably disposed on the flow cannula between an extended position in which the tip protector tube covers the entire injector tip, and a retracted position in which the tip protector tube is retracted proximally thereby exposing at least part of the injector tip. Accordingly, the tip protector tube protects the injector tip from being damaged while advancing the injector tip to a target injection site.

Abstract: Injector devices and methods for using them to deliver medicament into a patient's body, e.g., sub-retinally within an eye, are provided. The injector includes a cartridge including a piston slidably disposed within an interior for delivering medicament within the interior through an outlet, and a driver including a plunger coupled to the piston, a source of pressurized fluid, and an actuator member for opening a flow path at least partially between the source and the plunger to advance the plunger and piston to deliver medicament from the interior. One or more sensors are operatively coupled to the plunger to measure displacement of the plunger, a processor is coupled to the sensor(s) for analyzing sensor signals to measure volume of medicament delivered from the interior, and an output device, e.g., one or more LEDs or speakers, provide outputs related to the volume of medicament delivered.

Abstract: Injector devices and methods for using them to deliver medicament into a patient's body, e.g., sub-retinally within an eye, are provided. The injector includes an injector cannula having a soft injector tip. A retractable tip protector tube is slidably disposed on the flow cannula between an extended position in which the tip protector tube covers the entire injector tip, and a retracted position in which the tip protector tube is retracted proximally thereby exposing at least part of the injector tip. Accordingly, the tip protector tube protects the injector tip from being damaged while advancing the injector tip to a target injection site.

Abstract: The disclosure is directed to a flapper system and a flapper system kit that is compatible with both 2? and 3? flush valve seats. In some embodiments, the flapper system is configured to enable a user to select either a 2? or 3? flush valve seal for the flapper system. In some embodiments, the flapper system includes a pivot that enables sealing of a flat flush valve seat or an angled flush valve seat. In some embodiments, the flapper system includes one or more adjustable window assemblies that control a fluid flowrate within an internal portion of the flapper system to control buoyancy. In some embodiments, the flapper system includes an adaptor that converts a 2? valve into a 3? valve.

Abstract: This disclosure describes a kit comprising component for removing, replacing, and/or sealing toilet parts. In some embodiments, the kit comprises a flush valve assembly, fill valve assembly, a handle assembly, two tools, two gaskets, and packaging that also serves as one or more water containers. In some embodiments, the two gaskets are two conventional gaskets that can be combined to make a third gasket. In some embodiments, the combination of the two gaskets allows the creation of a synergistic gasket for sealing a tank-to-bowl interface than neither gasket could seal individually.

Abstract: The present disclosure provides extended or sustained release compositions of a dihydropyridine calcium channel blocker, specifically isradipine, and method of using said compositions for the treatment of neurological disorders, wherein the composition provides sustained plasma levels of the dihydropyridine calcium channel blocker.

Abstract: Compositions and methods are provided for administering a pharmaceutical composition to a human patient. Compositions are administered to a human patient orally, once daily, at a therapeutically effective dose. The pharmaceutical compositions comprise a drug selected from the group consisting of brivaracetam, divalproex, lacosamide, levetiracetam, oxcarbazepine, vigabatrin, and pharmaceutically acceptable salts of any of the foregoing, and at least one excipient. At least one of said at least one excipients modifies the release of said drug to provide an extended release form. The pharmaceutical composition have pharmacokinetic properties recited in the claims.

Abstract: Disclosed herein are multi-layer metal circuits, such as printed circuit boards (PCBs), with single-sided, partially-shielded, or fully-shielded via-less common-mode filters. The multi-layer metal circuits comprise at least one shield layer, at least one signal trace, and at least one reference layer (e.g., ground). The reference layer comprises a pattern of the via-less common-mode filter. The pattern may comprise, for example, a single piece-wise linear segment, or two or more disjoint and non-intersecting segments (which may be strictly linear or piece-wise linear). The reference layer is electrically isolated from the shield layer, and thus the via-less common-mode filters do not require vias. In addition to being used in PCBs, the disclosed multi-layer metal circuits may also be used in other applications, such as integrated circuits (e.g., implemented in semiconductor chips).

Abstract: A fast charging station, battery system and method for charging battery systems can be applied to most battery types in use for electric vehicles (EVs), electronic devices, and wireless electrical machines. The system provides for two or more charging ports in the electronic device, such as an EV, that may be able to receive and recognize a charging type, such as charging voltage, current and the like, and provide directed charging to multiple battery sub-packs that make up the entire battery. By charging sub-packs in parallel, the charge time can be substantially reduced. The system further provides a charging station with two or more electrical connections provided at each stall, providing for fast charge of an electrical device, such as an EV, positioned at each stall.

Abstract: Compositions and methods are provided for administering a pharmaceutical composition to a human patient. Compositions are administered to a human patient orally, once daily, at a therapeutically effective dose. The pharmaceutical compositions comprise a drug selected from the group consisting of brivaracetam, divalproex, lacosamide, levetiracetam, oxcarbazepine, vigabatrin, and pharmaceutically acceptable salts of any of the foregoing, and at least one excipient. At least one of said at least one excipients modifies the release of said drug to provide an extended release form. The pharmaceutical composition have pharmacokinetic properties recited in the claims.

Abstract: A fast charging battery system and method for charging battery systems can be applied to most battery types in use for electric vehicles (EVs), electronic devices, and wireless electrical machines. The system could employ industry proven battery charger systems and off-the-shelf electrical components (e.g., contactors, relay switches, semiconductor parts, DC-DC converters, and the like) to keep cost and complexity low. The system provides for two or more charging ports in the electronic device, such as an EV, that may be able to receive and recognize a charging type, such as charging voltage, current and the like, and provide directed charging to multiple battery sub-packs that make up the entire battery. By charging sub-packs in parallel, the charge time can be substantially reduced.

Abstract: Compositions and methods are provided for administering a pharmaceutical composition to a human patient. Compositions are administered to a human patient orally, once daily, at a therapeutically effective dose. The pharmaceutical compositions comprise a drug selected from the group consisting of brivaracetam, divalproex, lacosamide, levetiracetam, oxcarbazepine, vigabatrin, and pharmaceutically acceptable salts of any of the foregoing, and at least one excipient. At least one of said at least one excipients modifies the release of said drug to provide an extended release form. The pharmaceutical composition have pharmacokinetic properties recited in the claims.

Abstract: A fast charging station, battery system and method for charging battery systems can be applied to most battery types in use for electric vehicles (EVs), electronic devices, and wireless electrical machines. The system provides for two or more charging ports in the electronic device, such as an EV, that may be able to receive and recognize a charging type, such as charging voltage, current and the like, and provide directed charging to multiple battery sub-packs that make up the entire battery. By charging sub-packs in parallel, the charge time can be substantially reduced. The system further provides a charging station with two or more electrical connections provided at each stall, providing for fast charge of an electrical device, such as an EV, positioned at each stall.

Abstract: A fast charging battery system and method for charging battery systems can be applied to most battery types in use for electric vehicles (EVs), electronic devices, and wireless electrical machines. The system could employ industry proven battery charger systems and off-the-shelf electrical components (e.g., contactors, relay switches, semiconductor parts, DC-DC converters, and the like) to keep cost and complexity low. The system provides for two or more charging ports in the electronic device, such as an EV, that may be able to receive and recognize a charging type, such as charging voltage, current and the like, and provide directed charging to multiple battery sub-packs that make up the entire battery. By charging sub-packs in parallel, the charge time can be substantially reduced.

Abstract: A fast charging battery system and method for charging battery systems can be applied to most battery types in use for electric vehicles (EVs), electronic devices, and wireless electrical machines. The system could employ industry proven battery charger systems and off-the-shelf electrical components (e.g., contactors, relay switches, semiconductor parts, DC-DC converters, and the like) to keep cost and complexity low. The system provides for two or more charging ports in the electronic device, such as an EV, that may be able to receive and recognize a charging type, such as charging voltage, current and the like, and provide directed charging to multiple battery sub-packs that make up the entire battery. By charging sub-packs in parallel, the charge time can be substantially reduced.

Abstract: This disclosure describes a kit comprising component for removing, replacing, and/or sealing toilet parts. In some embodiments, the kit comprises a flush valve assembly, fill valve assembly, a handle assembly, two tools, two gaskets, and packaging that also serves as one or more water containers. In some embodiments, the two gaskets are two conventional gaskets that can be combined to make a third gasket. In some embodiments, the combination of the two gaskets allows the creation of a synergistic gasket for sealing a tank-to-bowl interface than neither gasket could seal individually.

Abstract: Compositions and methods are provided for administering a pharmaceutical composition to a human patient. Compositions are administered to a human patient orally, once daily, at a therapeutically effective dose. The pharmaceutical compositions comprise a drug selected from the group consisting of brivaracetam, divalproex, lacosamide, levetiracetam, oxcarbazepine, vigabatrin, and pharmaceutically acceptable salts of any of the foregoing, and at least one excipient. At least one of said at least one excipients modifies the release of said drug to provide an extended release form. The pharmaceutical composition have pharmacokinetic properties recited in the claims.

Abstract: Provided are methods for and compounds for modulating the complement system. In particular, compounds are provided that inhibit complement activation and compounds are provided that promote complement activation. The compounds are therapeutics by virtue of their effects on the complement system. Hence, the compounds that inhibit complement activation can be used for treatment of ischemic and reperfusion disorders, including myocardial infarction and stroke, sepsis, autoimmune diseases, inflammatory diseases and diseases with an inflammatory component, including Alzheimer's Disease and other neurodegenerative disorders.

Abstract: The present disclosure generally relates to a shielded patterned ground structure in a PCB. The PCB may be disposed in a hard disk drive. Conductive traces in PCBs can have the problem of common mode current flowing through the traces and thus increasing the magnitude of EMI noise. By providing a shielded patterned ground structure, the common mode current is reduced as is the magnitude of EMI noise, yet there is no negative impact to the differential signal.

Abstract: Compositions and methods are provided for administering a pharmaceutical composition to a human patient. Compositions are administered to a human patient orally, once daily, at a therapeutically effective dose. The pharmaceutical compositions comprise a drug selected from the group consisting of brivaracetam, divalproex, lacosamide, levetiracetam, oxcarbazepine, vigabatrin, and pharmaceutically acceptable salts of any of the foregoing, and at least one excipient. At least one of said at least one excipients modifies the release of said drug to provide an extended release form. The pharmaceutical composition have pharmacokinetic properties recited in the claims.